These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63 related articles for article (PubMed ID: 8461397)
1. Suppression of T-cell activation by administration of MHC class II-binding peptides. Adorini L; Guéry JC Immunol Ser; 1993; 59():331-43. PubMed ID: 8461397 [No Abstract] [Full Text] [Related]
2. Anti-V beta TcR monoclonal antibodies identify and can activate anergic T cells from mice rendered neonatally tolerant of class II alloantigens. Levy RB; Jones M; Streilein JW Transplant Proc; 1993 Feb; 25(1 Pt 1):360-1. PubMed ID: 8438335 [No Abstract] [Full Text] [Related]
3. Selective suppression of T-cell activation by administration of MHC class II-binding peptides. Adorini L Transplant Proc; 1992 Aug; 24(4 Suppl 2):14-6. PubMed ID: 1496683 [No Abstract] [Full Text] [Related]
4. Class II MHC/peptide complexes are released from APC and are acquired by T cell responders during specific antigen recognition. Patel DM; Arnold PY; White GA; Nardella JP; Mannie MD J Immunol; 1999 Nov; 163(10):5201-10. PubMed ID: 10553040 [TBL] [Abstract][Full Text] [Related]
5. A mutant antigen-presenting cell defective in antigen presentation expresses class II MHC molecules with an altered conformation. Dang LH; Lien LL; Benacerraf B; Rock KL J Immunol; 1993 May; 150(10):4206-17. PubMed ID: 8482833 [TBL] [Abstract][Full Text] [Related]
6. Turning tumor cells in situ into T-helper cell-stimulating, MHC class II tumor epitope-presenters: immuno-curing and immuno-consolidation. Hillman GG; Kallinteris NL; Lu X; Wang Y; Wright JL; Li Y; Wu S; Forman JD; Gulfo JV; Humphreys RE; Xu M Cancer Treat Rev; 2004 May; 30(3):281-90. PubMed ID: 15059651 [TBL] [Abstract][Full Text] [Related]
7. Carrier-independent hapten recognition and promiscuous MHC restriction by CD4 T cells induced by trinitrophenylated peptides. Kohler J; Hartmann U; Grimm R; Pflugfelder U; Weltzien HU J Immunol; 1997 Jan; 158(2):591-7. PubMed ID: 8992972 [TBL] [Abstract][Full Text] [Related]
8. Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy. Bonehill A; Heirman C; Thielemans K J Gene Med; 2005 Jun; 7(6):686-95. PubMed ID: 15693037 [TBL] [Abstract][Full Text] [Related]
9. Substitution of peptide bond 53-54 of HEL(52-61) with an ethylene bond rather than reduced peptide bond is tolerated by an MHC-II restricted T cell. Ettouati L; Salvi JP; Trescol-Biémont MC; Walchshofer N; Gerlier D; Rabourdin-Combe C; Paris J Pept Res; 1996; 9(5):248-53. PubMed ID: 9000251 [TBL] [Abstract][Full Text] [Related]
10. Function and regulation of MHC class II molecules in T-lymphocytes: of mice and men. Holling TM; Schooten E; van Den Elsen PJ Hum Immunol; 2004 Apr; 65(4):282-90. PubMed ID: 15120183 [TBL] [Abstract][Full Text] [Related]
11. Peptides corresponding to CD4-interacting regions of murine MHC class II molecules modulate immune responses of CD4+ T lymphocytes in vitro and in vivo. Shen X; Hu B; McPhie P; Wu X; Fox A; Germain RN; König R J Immunol; 1996 Jul; 157(1):87-100. PubMed ID: 8683160 [TBL] [Abstract][Full Text] [Related]
12. A peptide binding motif for I-Eg7, the MHC class II molecule that protects E alpha-transgenic nonobese diabetic mice from autoimmune diabetes. Gregori S; Trembleau S; Penna G; Gallazzi F; Hammer J; Papadopoulos GK; Adorini L J Immunol; 1999 Jun; 162(11):6630-40. PubMed ID: 10352280 [TBL] [Abstract][Full Text] [Related]
13. MHC class II presentation of endogenously expressed antigens by transfected dendritic cells. Diebold SS; Cotten M; Koch N; Zenke M Gene Ther; 2001 Mar; 8(6):487-93. PubMed ID: 11313828 [TBL] [Abstract][Full Text] [Related]
14. T-cell engagement of dendritic cells rapidly rearranges MHC class II transport. Boes M; Cerny J; Massol R; Op den Brouw M; Kirchhausen T; Chen J; Ploegh HL Nature; 2002 Aug; 418(6901):983-8. PubMed ID: 12198548 [TBL] [Abstract][Full Text] [Related]
15. Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway. Rock KL; Clark K J Immunol; 1996 May; 156(10):3721-6. PubMed ID: 8621907 [TBL] [Abstract][Full Text] [Related]
16. How the T cell repertoire becomes peptide and MHC specific. Huseby ES; White J; Crawford F; Vass T; Becker D; Pinilla C; Marrack P; Kappler JW Cell; 2005 Jul; 122(2):247-60. PubMed ID: 16051149 [TBL] [Abstract][Full Text] [Related]
17. Immunodominance does not result from peptide competition for MHC class II presentation. Lo-Man R; Langeveld JP; Martineau P; Hofnung M; Meloen RH; Leclerc C J Immunol; 1998 Feb; 160(4):1759-66. PubMed ID: 9469434 [TBL] [Abstract][Full Text] [Related]
18. Enhancement of experimental Graves' disease by intranasal administration of a T cell epitope of the thyrotropin receptor. Arima T; Shimojo N; Yamaguchi K; Tomiita M; Kohn LD; Kohno Y Clin Immunol; 2008 Apr; 127(1):7-13. PubMed ID: 18234558 [TBL] [Abstract][Full Text] [Related]
19. [Mechanism of autoantigen Ia recognition in T cell proliferative response]. Ishii N; Nagai R; Okuda K Arerugi; 1983 Sep; 32(9):996-8. PubMed ID: 6607722 [No Abstract] [Full Text] [Related]
20. [I-A restricted sulbenicillin specific T cell proliferative response in mice]. Kawaguchi H; Sato M; Ikezawa Z Nihon Hifuka Gakkai Zasshi; 1986 Jun; 96(7):699-703. PubMed ID: 3489850 [No Abstract] [Full Text] [Related] [Next] [New Search]